SCHEMBL31728476

SCHEMBL31728476

[2H]C([2H])([2H])Oc1cc(Br)c2ncnc(N)c2c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 1/20 0.35
▸ LIMK1 P53667 4/20 0.33
▸ KDR P35968 4/20 0.33
▸ CDC7 O00311 2/20 0.33
▸ PLK4 O00444 2/20 0.33
▸ AURKA O14965 2/20 0.33
▸ ROCK2 O75116 2/20 0.33
▸ PIM1 P11309 2/20 0.33
▸ PRKACA P17612 2/20 0.33
▸ RPS6KB1 P23443 2/20 0.33
▸ CDK2 P24941 2/20 0.33
▸ MARK3 P27448 2/20 0.33
▸ FLT4 P35916 2/20 0.33
▸ CSNK1D P48730 2/20 0.33
▸ GSK3A P49840 2/20 0.33
▸ STK3 Q13188 2/20 0.33
▸ ROCK1 Q13464 2/20 0.33
▸ DYRK1A Q13627 2/20 0.33
▸ MARK2 Q7KZI7 2/20 0.33
▸ AURKB Q96GD4 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31728053 0.90 PDE5A (0.44) PDE5ALIMK1KDRMAP4K4ADK
SCHEMBL31728083 0.83 PDE5A (0.35) PDE5ALIMK1KDRCDC7PLK4
SCHEMBL31727768 0.79 MAP4K4 (0.33) PDE5ALIMK1KDRCDC7PLK4
SCHEMBL31728605 0.78 KDR (0.35) PDE5AKDRFLT4MAP4K4RET
SCHEMBL31728812 0.77 ABL1 (0.32) PDE5AKDRABL1EGFRHCK
SCHEMBL31727727 0.75 PIK3CA (0.38) MAP4K4ADKEGFRPIK3CBPIK3CG
SCHEMBL31729158 0.73 PIK3CD (0.37) LIMK1KDRCDC7PLK4AURKA
SCHEMBL31728534 0.72 PDE5A (0.44) PDE5ALIMK1KDRCDC7PLK4
SCHEMBL31728538 0.72 AURKA (0.41) PDE5AKDRAURKAEGFRPOLB
SCHEMBL31728095 0.72 NQO2 (0.38) PDE5AKDRAURKARPS6KB1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback